Please Wait

Applying Filters...

Sumatriptan
NDC API
Table View

Molecular glue degraders: Lilly, AbbVie sign billion-dollar deals; BMS leads with three late-stage drugs

Data Compilation
#PharmaFlow

Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

Stock Recap
#PipelineProspector

Sumatriptan

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

51 API Suppliers, 26 USDMF, 14 CEP/COS, 4 JDMF, 13 EU WC, 6 KDMF, 18 NDC API, 26 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

6 Drugs in Development

6 Drugs in Development

INTERMEDIATES

5 Intermediate Suppliers

5 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

394 FDF Dossiers, 100 FDA Orange Book, 212 Europe, 33 Canada, 15 Australia, 19 South Africa, 15 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML), INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 100MG BASE, TABLET;ORAL - EQ 25MG BASE, TABLET;ORAL - EQ 50MG BASE, SYSTEM;IONTOPHORESIS - EQ 6.5MG BASE/4HR, POWDER;NASAL - EQ 11MG BASE, SPRAY;NASAL - 20MG/SPRAY, SPRAY;NASAL - 5MG/SPRAY, TABLET;ORAL - 500MG;EQ 85MG BASE, TABLET;ORAL - 60MG;EQ 10MG BASE, INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML), INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

RELATED EXCIPIENT COMPANIES

1 Actylis, 1 Finar

EXCIPIENTS BY APPLICATIONS

1 Topical, 1 Parenteral

DIGITAL CONTENT

35 News #PharmaBuzz

35 News #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 178 Regulatory FDF Prices, 8 Annual Reports

MARKET PLACE

11 APIs, 1 FDF Dossiers

PATENTS & EXCLUSIVITIES

49 US Patents, 10 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 3 USP, 5 Others

$ Xls download

Filters

Log in to access your PharmaMiles and download the data

Last Updated on PharmaCompass	Virtual Booth	Country	Labeler	NDC Package Code	Non Proprietary Name	Start Marketing Date	End Marketing Date	Category Code	Dosage Form (Strength)
28/03/2025	Dr. Reddy\'s Laboratories	India	Dr. Reddy¿s Laboratories Ltd.	55111-060	Sumatriptan Succinate	2003-03-21	2026-12-31	BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING	POWDER (1kg/kg)
28/03/2025	Moehs Iberica	Spain	Moehs Catalana SL	52932-0727	Sumatriptan Succinate	2009-10-28	2025-12-31	BULK INGREDIENT	POWDER (1kg/kg)

Contact us
to update this info

Sumatriptan

Sumatriptan

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

51 API Suppliers

26 USDMF

14 CEP/COS

4 JDMF

13 EU WC

6 KDMF

18 NDC API

26 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

6 Drugs in Development

INTERMEDIATES

5 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

394 FDF Dossiers

100 FDA Orange Book

212 Europe

33 Canada

15 Australia

19 South Africa

15 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 100MG BASE

TABLET;ORAL - EQ 25MG BASE

TABLET;ORAL - EQ 50MG BASE

SYSTEM;IONTOPHORESIS - EQ 6.5MG BASE/4HR

POWDER;NASAL - EQ 11MG BASE

SPRAY;NASAL - 20MG/SPRAY

SPRAY;NASAL - 5MG/SPRAY

TABLET;ORAL - 500MG;EQ 85MG BASE

TABLET;ORAL - 60MG;EQ 10MG BASE

INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

RELATED EXCIPIENT COMPANIES

1 Actylis

1 Finar

EXCIPIENTS BY APPLICATIONS

1 Topical

1 Parenteral

DIGITAL CONTENT

35 News #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions

178 Regulatory FDF Prices

8 Annual Reports

MARKET PLACE

11 APIs

1 FDF Dossiers

PATENTS & EXCLUSIVITIES

49 US Patents

10 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM

3 USP

5 Others

Filters

INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons